| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A453 | GSK-4381562 Featured |
|
|
| A454 | Anti-PVRIG Antibody (COM701) Featured |
|
|
| A455 | Foravirumab Featured | Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III. |
|
| A456 | Rafivirumab Featured | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails. |
|
| A457 | Medella patent anti-RAMP-3 Featured |
|
|
| A458 | 19G9 Featured |
|
|
| A459 | Elezanumab Featured | Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism. |
|
| A460 | Anti-RGMC/HFE2 Antibody (DISC-0974) Featured |
|
|
| A461 | Roledumab Featured | Roledumab (LFB-R593) is a human IgG1-κ antibody targeting RHD/CD240D. Roledumab is expressed by YB2/0 rat hybridoma cells. |
|
| A462 | LFB Anti-RhD Featured |
|
|
| A463 | Asclepius Technology patent anti-Robo1 CAR Featured |
|
|
| A464 | Zilovertamab Featured | Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling. |
|
| A465 | Ozuriftamab Featured | Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC. |
|
| A466 | Oncomed patent anti-RSPO1 Featured |
|
|
| A467 | Rosmantuzumab Featured | Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors. |
|
| A468 | Palivizumab Featured | Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice. |
|
| A469 | Motavizumab Featured | Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research. |
|
| A470 | Ozanezumab Featured | Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research. |
|
| A471 | Atinumab Featured | Atinumab (6A3-IgG4) is an antibody. Teropavimab can be used for the research of spinal cord injury (SCI). |
|
| A472 | Atinumab (NG-101) Featured |
|
|
| A473 | LK-1 Featured |
|
|
| A474 | CDX-0158 Featured |
|
|
| A475 | LOP628 Featured |
|
|
| A476 | Wuhan U. patent anti-Nav1.9 Featured |
|
|
| A477 | Duke anti-NAv1.7 Featured |
|
|
| A478 | Pepinemab Featured | Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D. |
|
| A479 | Sanofi patent anti-PAI-1 Featured |
|
|
| A480 | Abbv-011 Featured |
|
|
| A481 | Pritoxaximab Featured | Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1. |
|
| A482 | Setoxaximab Featured | Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1. |
|
